Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a distinct subset of breast cancer that results from overexpression of HER2 protein. Pertuzumab—a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2—was recently approved f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Kei, Morii, Nao, Yamashiro, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827570/
https://www.ncbi.nlm.nih.gov/pubmed/31802990
http://dx.doi.org/10.2147/CE.S217848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827570/
https://www.ncbi.nlm.nih.gov/pubmed/31802990
http://dx.doi.org/10.2147/CE.S217848

Ejemplares similares